JUN and metabolic dysfunction-associated steatohepatitis: RA treatment reversed the increase in MyD88, c-Fos, and c-Jun mRNA levels and decreased TLR4 mRNA levels by 37% in comparison with those of the NASH group (Fig. 8B).